Challenging targets, such as membrane proteins or protein-protein interactions were considered undruggable in the past. However, today a variety of screening methods can be used to help develop drugs against these formerly undruggable targets.

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.  

Chronic neurodegenerative diseases encompass a variety of progressive conditions that affect neurons, including Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, and other forms of dementia. They are among the most common and challenging central nervous system (CNS) diseases. “Many companies had stopped their research program into neurodegenerative diseases, but now sophisticated technology advances have became more broadly …Read More >

Syntheses of specifically functionalized molecules continue to be rate limiting steps (RLS) in drug discovery. Improvement in this RLS means investing only in reactions/synthetic sequences that are more likely to succeed. Structural diversifications, different substitution patterns or unique heterocyclic systems can often adversely impact the crucial step(s) of established synthetic sequences or development of feasible …Read More >